- Before
- Reads the overnight agency output, decides who must know and chases the owners by email, looking for the one update that moves a filing.
- Now
- Opens a front page led by the update that moves a filing, reads the two paragraphs that matter and signs; the teams are told that morning.
Regulatory intelligence on one morning: a revised EMA draft and a PMDA notice
One weekday morning in the sample. Overnight, EMA published a revised drug–device quality guideline for consultation, and PMDA, FDA and NMPA each issued something that touches four products in the portfolio, among them a biologic, a stent and a glucose monitor. Here is what happens next, screen by screen, in the working solution.
A worked example on sample data. Names, IDs and figures on the screens and in this section come from the demo.
- 0105:00 to 05:12 CET
Sixty-four sources checked before anyone is at a desk
The agentsThe agency watcher checks 64 sources in 38 countries and finds 41 changed pages, 27 new updates once duplicates are removed. The translator renders 9 documents from Japanese, Chinese, German and Portuguese, originals kept. The version comparer checks 3 revised documents against the versions they replace: 22 changed paragraphs, 5 of which change a plan. The impact assessor proposes 5 High, 8 Medium, 10 Low and 4 not relevant.
“Chose the lead: highest impact on your products. EMA drug–device draft · the biologic's autoinjector.” 05:12
- 02Morning
The Regulatory Morning, led by the update that matters most to the portfolio
Regulatory intelligence leadThe edition printed at 05:12 CET: 27 updates, 9 agencies, 64 sources checked. The lead story is EMA's draft revision of the drug–device quality guideline, which puts the biologic's switch to an autoinjector in scope. Beside it: a labeling format change for the biologic with two deadlines on the same day, the edition's deadlines, and 13 High and Medium impacts waiting for a signature. Below, a column each for FDA, EMA, PMDA / MHLW, NMPA and MHRA.
“High and Medium impacts. Teams are told only after a lead signs.”
- 03What changed
Two of eleven changed paragraphs change the plan
Version comparerAgainst the 2019 guideline in force, 11 paragraphs changed: 6 editorial, 3 that need a check and 2 that change the plans. §4.2 is rewritten: a variation that changes the device part of an integral product now needs comparability data and a Notified Body Opinion, which lands on the biologics regulatory lead. §4.3 is new: moving from prefilled syringe to autoinjector needs delivered-dose, dose-accuracy and injection-time comparability on three batches, which lands on device engineering.
The comparer works against the version the agency names as replaced, word for word.
- 04Sign
The lead confirms the impact, with the meaning of the signature
Regulatory intelligence leadThe plan view shows three new steps for the autoinjector's EU variation: book the notified body, the notified body opinion, and two more delivered-dose batches over the winter. The planned filing month holds only if the notified body is booked by a set date. The lead confirms the autoinjector as High and the prefilled syringe as Medium, leaves the three teams ticked to be notified and signs: “I confirm this impact assessment”.
“Signed electronically: your name, date, time and meaning go on the audit trail.”
- 0509:14 CET
Each team gets its exact paragraphs that morning
Digest writerThe impact is confirmed at 09:14. Biologics regulatory gets §4.2, Device engineering gets §4.3, §5.3 and §6, and Regulatory policy gets §8, each note with the original document attached. Nothing was sent before the signature.
“Impact confirmed · Biologics regulatory, Device engineering and Regulatory policy notified”
- 06The second lead
A Japanese notice, read beside its translation
Translator and SummarizerAn MHLW notice puts the biologic in the first wave of XML format 2.0 for electronic package inserts: each section goes into structured fields, and the re-issued insert must be on the PMDA website by a set date. Each paragraph of the original sits next to its English translation, and each summary line links to its passage. The impact assessor proposes High for Japan, 95% confident.
“The labeling plan puts the Japan label update in a later cycle. The notice requires posting about 10 weeks earlier.”
- 07One question
“Does the new PMDA notice change our labeling timeline?”
Regulatory intelligence leadThe assistant searches 4,812 updates and 3 internal plans, reads the notice in Japanese and checks the labeling plan. Yes: it moves the Japan label update for the biologic forward by about 10 weeks, and the EU asks for the same product information in the ePI standard, due the same day. The sources open beside the answer: the Japanese passage highlighted with its translation, and the Japan row of the labeling plan.
“Next step: open a Japan label change now and add the wording to the core data sheet, so both markets move together.”
- 08All 27
The rest of the edition behind the front page, in one list
Regulatory intelligence leadThe other updates sit in one list: 5 High, 8 Medium, 10 Low, 4 not relevant, filterable by agency and product and searchable in any language, translated titles beside the original. Each row carries its deadline: comments close on the EMA draft in 117 days, and comments on the FDA stent draft are due by year end.
- 09Across the portfolio
Open impacts by product and agency
Devices regulatory leadThe impact board lays the open impacts out by product and agency, then by stage: 13 new and waiting for confirmation, 3 assessed with teams working, 4 actioned. The stent carries three FDA impacts, led by the revised stent draft that asks for five years of follow-up where the PMA supplement plans three. Fourteen Low and Not relevant updates were filed automatically today.
- 10This year
Within hours of publication, where it used to take a week
Regulatory intelligence leadThe dashboard shows 3,977 updates read this year from 64 sources in 38 countries, and a median of 3.4 hours from publication to the owning team, against 7.6 days by hand the year before. 714 High and Medium impacts were confirmed this year, each signed by a named lead; 96% were confirmed within 2 working days, and leads kept the agent's proposed impact 91% of the time.
“Each High and Medium impact this year was confirmed by a named lead before teams were notified.”